Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch...
24 KB (2,250 words) - 06:06, 16 July 2024
to amend certain terms around the development and commercialization of filgotinib. In June 2022, the business announced it would acquire CellPoint for €125...
6 KB (408 words) - 04:22, 18 January 2024
and vitiligo. Examples are tofacitinib, baricitinib, upadacitinib and filgotinib. In 2014 researchers discovered that oral JAK inhibitors, when administered...
9 KB (974 words) - 14:46, 22 June 2024
numbers of T-lymphocytes etc. unknown etanercept decoy TNF receptor bDMARD filgotinib Janus kinase (JAK) inhibitor tsDMARD golimumab TNF inhibitor bDMARD gold...
10 KB (869 words) - 20:47, 1 July 2024
JAK1 Abrocitinib Baricitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480...
31 KB (3,413 words) - 23:30, 21 June 2024
JAK1 Abrocitinib Baricitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480...
34 KB (3,877 words) - 13:28, 13 July 2024
JAK1 Abrocitinib Baricitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480...
33 KB (2,917 words) - 16:32, 16 July 2024
JAK1 Abrocitinib Baricitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480...
26 KB (2,102 words) - 02:19, 16 July 2024
Agency (EMA) recommends that the Janus kinase inhibitors abrocitinib, filgotinib, baricitinib, upadacitinib, and tofacitinib should be used in the following...
36 KB (2,981 words) - 17:57, 23 June 2024
JAK1 Abrocitinib Baricitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib JAK2 Atiprimod AZD-1480...
23 KB (2,088 words) - 01:05, 8 April 2024